-+ 0.00%
-+ 0.00%
-+ 0.00%

WuXi XDC secures GMP release for BCM3 bioconjugate production line in Singapore

PUBT·08/18/2026 04:04:41
Listen to the news
WuXi XDC secures GMP release for BCM3 bioconjugate production line in Singapore
  • WuXi XDC secured GMP release for its BCM3 bioconjugate production line at its Singapore site.
  • Facility supports commercial manufacturing for antibody intermediates, 200-2,000 L batches, conjugated drug substances up to 2,000 L.
  • BCM3 is WuXi XDC’s first overseas GMP-released facility, expanding global capacity alongside its Wuxi BCM1, BCM2 lines.
  • Drug product filling line DP4 at the Singapore site is scheduled to reach GMP release by end-August 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608180003PR_NEWS_USPR_____CN28415) on August 18, 2026, and is solely responsible for the information contained therein.